Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acoramidis switch study in tafamidis-pretreated ATTR-CM
2025-521831-35-00Phase 4Authorised
- Sponsor
- Bayer Consumer Health
- Start
- Feb 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 4, open-label, single-arm trial of tarlatamab in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by Bayer Consumer Health. Primary endpoint: Change in serum transthyretin level from baseline to month 6 or premature discontinuation. Planned start Feb 2026; status: authorised.
02
Drugs
tarlatamab
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on 2025-521831-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521831-35-00.